NASDAQ:EXAI Exscientia (EXAI) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free EXAI Stock Alerts $5.38 -0.51 (-8.66%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$5.23▼$5.8050-Day Range$3.99▼$6.0452-Week Range$3.86▼$9.12Volume706,312 shsAverage Volume533,492 shsMarket Capitalization$650.39 millionP/E RatioN/ADividend YieldN/APrice Target$9.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Exscientia alerts: Email Address Exscientia MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside81.2% Upside$9.75 Price TargetShort InterestHealthy3.66% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.03Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.07) to ($1.04) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.85 out of 5 starsMedical Sector579th out of 903 stocksBiological Products, Except Diagnostic Industry97th out of 152 stocks 3.3 Analyst's Opinion Consensus RatingExscientia has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageExscientia has only been the subject of 1 research reports in the past 90 days.Read more about Exscientia's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.66% of the float of Exscientia has been sold short.Short Interest Ratio / Days to CoverExscientia has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Exscientia has recently decreased by 0.91%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldExscientia does not currently pay a dividend.Dividend GrowthExscientia does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EXAI. Previous Next 2.2 News and Social Media Coverage News SentimentExscientia has a news sentiment score of 0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Exscientia this week, compared to 4 articles on an average week.Search InterestOnly 8 people have searched for EXAI on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows26 people have added Exscientia to their MarketBeat watchlist in the last 30 days. This is an increase of 4% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exscientia insiders have not sold or bought any company stock.Percentage Held by Insiders16.40% of the stock of Exscientia is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.58% of the stock of Exscientia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exscientia's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exscientia are expected to grow in the coming year, from ($1.07) to ($1.04) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exscientia is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exscientia is -4.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExscientia has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Exscientia's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? It's true.Click here to register for free. About Exscientia Stock (NASDAQ:EXAI)Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company's lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies. The company has collaboration agreements with Merck KGaA, Bristol Myers Squibb, Sanofi, Bill & Melinda Gates Foundation, Charité Universitätsmedizin Berlin, Rallybio, and GT Apeiron Therapeutics. Exscientia plc was founded in 2012 and is headquartered in Oxford, the United Kingdom.Read More EXAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAI Stock News HeadlinesJune 8 at 10:36 AM | globenewswire.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAIJune 7 at 8:00 PM | prnewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action - EXAIJune 7 at 5:08 PM | businesswire.comEXAI INVESTOR ALERT: Kirby McInerney LLP Reminds Exscientia p.l.c. (EXAI) Investors of Upcoming Lead Plaintiff Deadline in Class Action LawsuitJune 7 at 1:18 PM | globenewswire.comLevi & Korsinsky Notifies Exscientia plc Investors of a Class Action Lawsuit and Upcoming Deadline – EXAIJune 7 at 11:50 AM | businesswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Exscientia plc and Encourages Investors with Losses to Contact the FirmJune 6 at 3:31 PM | globenewswire.comShareholders that lost money on Exscientia plc(EXAI) Urged to Join Class Action – Contact The Gross Law Firm to Learn MoreJune 6 at 11:10 AM | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaJune 6 at 10:10 AM | globenewswire.comLowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmJune 6 at 7:00 AM | businesswire.comExscientia Appoints New Leaders to Strengthen the Impact of Integrated Technologies and Focus Clinical Development Expertise in OncologyJune 6 at 5:45 AM | prnewswire.comExscientia plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAIJune 5, 2024 | globenewswire.comEXAI STOCKHOLDERS – Contact Robbins LLP for Information About the Pending Lead Plaintiff Deadline in the Exscientia plc Class ActionJune 5, 2024 | prnewswire.comIMPORTANT JUNE DEADLINE REMINDER: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the FirmJune 5, 2024 | globenewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaJune 5, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Exscientia p.l.c. of Class Action Lawsuit and Upcoming Deadlines – EXAIJune 5, 2024 | prnewswire.comShareholders that lost money on Exscientia plc(EXAI) should contact The Gross Law Firm about pending Class Action - EXAIJune 5, 2024 | globenewswire.comEXAI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Exscientia p.l.c. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!June 4, 2024 | prnewswire.comSHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Exscientia plc with Losses to Contact the FirmJune 4, 2024 | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitJune 4, 2024 | prnewswire.comExscientia plc Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before June 25, 2024 to Discuss Your Rights - EXAIJune 4, 2024 | globenewswire.comEXSCIENTIA PLC (NASDAQ: EXAI) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Exscientia plcJune 3, 2024 | globenewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Exscientia p.l.c Investors to Secure Counsel Before Important Deadline in Securities Class Action – EXAIJune 3, 2024 | globenewswire.comExscientia p.l.c. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law FirmJune 3, 2024 | globenewswire.comLowey Dannenberg Notifies Exscientia p.l.c. (“Exscientia” or the “Company”) (NASDAQ: EXAI) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $50,000 in Losses to Contact the FirmMay 31, 2024 | prnewswire.comEXAI Investors Have Opportunity to Lead Exscientia p.l.c. Securities Fraud LawsuitMay 31, 2024 | prnewswire.comDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ExscientiaSee More Headlines Receive EXAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exscientia and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/21/2024Today6/09/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:EXAI CUSIPN/A CIK1865408 Webwww.exscientia.ai Phone44-0-18-6581-8941FaxN/AEmployees483Year FoundedN/APrice Target and Rating Average Stock Price Target$9.75 High Stock Price Target$13.00 Low Stock Price Target$7.00 Potential Upside/Downside+81.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-181,560,000.00 Net Margins-666.80% Pretax Margin-737.98% Return on Equity-34.59% Return on Assets-24.67% Debt Debt-to-Equity Ratio0.05 Current Ratio6.30 Quick Ratio6.30 Sales & Book Value Annual Sales$25.60 million Price / Sales25.41 Cash FlowN/A Price / Cash FlowN/A Book Value$3.66 per share Price / Book1.47Miscellaneous Outstanding Shares120,890,000Free Float101,062,000Market Cap$650.39 million OptionableOptionable Beta0.85 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. David Hallett Ph.D. (Age 55)Chief Scientific Officer, Interim CEO, Principal Executive Officer & Executive Director Mr. Ben R. Taylor (Age 47)CFO, Chief Strategy Officer & Executive Director Comp: $534.97kDr. Michael Krams M.D. (Age 63)Chief Medical Officer Ms. Eileen Jennings-BrownChief Information OfficerMs. Sara ShermanVice President of Investor RelationsMr. Dan IrelandExecutive VP of Legal & Company SecretaryMr. Parker MossExecutive Vice President of Corporate DevelopmentMs. Caroline RowlandChief People OfficerMr. Richard LawChief Business OfficerDr. John P. Overington Ph.D.Chief Data OfficerMore ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLSchrödingerNASDAQ:SDGRNovavaxNASDAQ:NVAXApogee TherapeuticsNASDAQ:APGEADMA BiologicsNASDAQ:ADMAView All CompetitorsInstitutional OwnershipPlatinum Investment Management Ltd.Sold 141,500 shares on 5/14/2024Ownership: 3.265%EntryPoint Capital LLCBought 5,784 shares on 5/14/2024Ownership: 0.026%Mitsubishi UFJ Trust & Banking CorpSold 25,530 shares on 5/10/2024Ownership: 0.125%Susquehanna Portfolio Strategies LLCSold 13,169 shares on 5/7/2024Ownership: 0.028%Baillie Gifford & Co.Sold 116,075 shares on 5/1/2024Ownership: 3.784%View All Institutional Transactions EXAI Stock Analysis - Frequently Asked Questions Should I buy or sell Exscientia stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exscientia in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" EXAI shares. View EXAI analyst ratings or view top-rated stocks. What is Exscientia's stock price target for 2024? 4 equities research analysts have issued twelve-month target prices for Exscientia's shares. Their EXAI share price targets range from $7.00 to $13.00. On average, they anticipate the company's stock price to reach $9.75 in the next year. This suggests a possible upside of 81.2% from the stock's current price. View analysts price targets for EXAI or view top-rated stocks among Wall Street analysts. How have EXAI shares performed in 2024? Exscientia's stock was trading at $6.41 at the beginning of the year. Since then, EXAI stock has decreased by 16.1% and is now trading at $5.38. View the best growth stocks for 2024 here. When is Exscientia's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our EXAI earnings forecast. How were Exscientia's earnings last quarter? Exscientia plc (NASDAQ:EXAI) issued its earnings results on Thursday, March, 21st. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.44) by $0.02. The business had revenue of $3.10 million for the quarter, compared to analyst estimates of $41.63 million. Exscientia had a negative net margin of 666.80% and a negative trailing twelve-month return on equity of 34.59%. What ETFs hold Exscientia's stock? ETFs with the largest weight of Exscientia (NASDAQ:EXAI) stock in their portfolio include First Trust Nasdaq Artificial Intelligence and Robotics ETF (ROBT), Loncar China Biopharma ETF (CHNA) and Range Cancer Therapeutics ETF (CNCR).Virtus LifeSci Biotech Clinical Trials ETF (BBC). When did Exscientia IPO? Exscientia (EXAI) raised $291 million in an initial public offering on Friday, October 1st 2021. The company issued 13,850,000 shares at a price of $20.00-$22.00 per share. Who are Exscientia's major shareholders? Exscientia's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (3.78%), Platinum Investment Management Ltd. (3.26%), Mitsubishi UFJ Trust & Banking Corp (0.13%), Susquehanna Portfolio Strategies LLC (0.03%), EntryPoint Capital LLC (0.03%) and China Universal Asset Management Co. Ltd. (0.01%). How do I buy shares of Exscientia? Shares of EXAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:EXAI) was last updated on 6/9/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exscientia plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Exscientia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.